ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of April 19, 2024, ALGS stock price declined to $0.75 with 137,815 million shares trading.

ALGS has a beta of 2.84, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.17 to the broad based SPY ETF.

ALGS has a market cap of $56.75 million. This is considered a Micro Cap stock.

Last quarter Aligos Therapeutics reported $2 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $409,000 and exceeded earnings estimates by $.05.

In the last 3 years, ALGS stock traded as high as $34.31 and as low as $.54.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC.

ALGS has underperformed the market in the last year with a price return of -24.2% while the SPY ETF gained +21.2%. However, in the short term, ALGS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.5% vs +3.0% return in SPY. But in the last 2 weeks, ALGS shares have been beat by the market, returning -27.9% compared to an SPY return of -4.5%.

ALGS support price is $.75 and resistance is $.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS stock will trade within this expected range on the day.